nodes	percent_of_prediction	percent_of_DWPC	metapath
Progesterone—ABCC1—Dactinomycin—testicular cancer	0.0561	0.0804	CbGbCtD
Progesterone—ABCB11—Vinblastine—testicular cancer	0.0495	0.0709	CbGbCtD
Progesterone—CYP2A6—Ifosfamide—testicular cancer	0.0479	0.0686	CbGbCtD
Progesterone—ABCC1—Epirubicin—testicular cancer	0.0406	0.0582	CbGbCtD
Progesterone—ABCC1—Vinblastine—testicular cancer	0.0352	0.0504	CbGbCtD
Progesterone—CYP3A7—Ifosfamide—testicular cancer	0.0328	0.0469	CbGbCtD
Progesterone—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0328	0.0469	CbGbCtD
Progesterone—SLC22A2—Vinblastine—testicular cancer	0.0319	0.0457	CbGbCtD
Progesterone—ABCC1—Etoposide—testicular cancer	0.0317	0.0454	CbGbCtD
Progesterone—ABCB11—Doxorubicin—testicular cancer	0.0304	0.0436	CbGbCtD
Progesterone—CYP1B1—Doxorubicin—testicular cancer	0.0304	0.0436	CbGbCtD
Progesterone—SLC22A2—Cisplatin—testicular cancer	0.0292	0.0419	CbGbCtD
Progesterone—CYP3A5—Ifosfamide—testicular cancer	0.0246	0.0352	CbGbCtD
Progesterone—CYP2C8—Ifosfamide—testicular cancer	0.0236	0.0338	CbGbCtD
Progesterone—ABCC1—Doxorubicin—testicular cancer	0.0216	0.0309	CbGbCtD
Progesterone—ABCC1—Methotrexate—testicular cancer	0.0209	0.03	CbGbCtD
Progesterone—CYP2C19—Ifosfamide—testicular cancer	0.0198	0.0284	CbGbCtD
Progesterone—CYP2C9—Ifosfamide—testicular cancer	0.0165	0.0236	CbGbCtD
Progesterone—CYP17A1—seminiferous tubule of testis—testicular cancer	0.0152	0.137	CbGeAlD
Progesterone—ABCB1—Dactinomycin—testicular cancer	0.0135	0.0194	CbGbCtD
Progesterone—PGR—corpus luteum—testicular cancer	0.012	0.109	CbGeAlD
Progesterone—CYP3A5—Etoposide—testicular cancer	0.0117	0.0168	CbGbCtD
Progesterone—SHBG—seminiferous tubule of testis—testicular cancer	0.0113	0.102	CbGeAlD
Progesterone—CYP2C8—Etoposide—testicular cancer	0.0113	0.0162	CbGbCtD
Progesterone—AR—scrotum—testicular cancer	0.0104	0.0944	CbGeAlD
Progesterone—CYP3A4—Ifosfamide—testicular cancer	0.00958	0.0137	CbGbCtD
Progesterone—CYP1A2—Etoposide—testicular cancer	0.00874	0.0125	CbGbCtD
Progesterone—ABCB1—Vinblastine—testicular cancer	0.00848	0.0122	CbGbCtD
Progesterone—AR—seminiferous tubule of testis—testicular cancer	0.00811	0.0734	CbGeAlD
Progesterone—CYP2C9—Cisplatin—testicular cancer	0.00801	0.0115	CbGbCtD
Progesterone—CYP2D6—Vinblastine—testicular cancer	0.00799	0.0114	CbGbCtD
Progesterone—ABCB1—Cisplatin—testicular cancer	0.00778	0.0111	CbGbCtD
Progesterone—ABCB1—Etoposide—testicular cancer	0.00764	0.0109	CbGbCtD
Progesterone—SHBG—semen—testicular cancer	0.00625	0.0566	CbGeAlD
Progesterone—ABCB1—Doxorubicin—testicular cancer	0.00521	0.00747	CbGbCtD
Progesterone—CYP3A4—Vinblastine—testicular cancer	0.00508	0.00728	CbGbCtD
Progesterone—ABCB1—Methotrexate—testicular cancer	0.00505	0.00723	CbGbCtD
Progesterone—CYP2D6—Doxorubicin—testicular cancer	0.00491	0.00704	CbGbCtD
Progesterone—CYP3A4—Etoposide—testicular cancer	0.00458	0.00656	CbGbCtD
Progesterone—AR—semen—testicular cancer	0.00449	0.0406	CbGeAlD
Progesterone—CYP3A4—Doxorubicin—testicular cancer	0.00312	0.00447	CbGbCtD
Progesterone—PGR—Ovarian Infertility Genes—DAZL—testicular cancer	0.00217	0.213	CbGpPWpGaD
Progesterone—SLC10A1—seminal vesicle—testicular cancer	0.00204	0.0185	CbGeAlD
Progesterone—SLC10A1—gonad—testicular cancer	0.00147	0.0133	CbGeAlD
Progesterone—CYP2A6—seminal vesicle—testicular cancer	0.00137	0.0124	CbGeAlD
Progesterone—CYP17A1—gonad—testicular cancer	0.00128	0.0116	CbGeAlD
Progesterone—NR3C2—seminal vesicle—testicular cancer	0.00128	0.0116	CbGeAlD
Progesterone—SLC22A3—embryo—testicular cancer	0.00116	0.0105	CbGeAlD
Progesterone—SLC22A3—seminal vesicle—testicular cancer	0.00109	0.00989	CbGeAlD
Progesterone—SLC10A1—testis—testicular cancer	0.00106	0.00961	CbGeAlD
Progesterone—SIGMAR1—seminal vesicle—testicular cancer	0.00106	0.00956	CbGeAlD
Progesterone—ABCB11—testis—testicular cancer	0.00105	0.0095	CbGeAlD
Progesterone—CYP17A1—female gonad—testicular cancer	0.00104	0.00944	CbGeAlD
Progesterone—ESR1—embryo—testicular cancer	0.000994	0.00899	CbGeAlD
Progesterone—SHBG—gonad—testicular cancer	0.000958	0.00866	CbGeAlD
Progesterone—AR—seminal vesicle—testicular cancer	0.000951	0.0086	CbGeAlD
Progesterone—CYP17A1—testis—testicular cancer	0.000926	0.00838	CbGeAlD
Progesterone—ABCC1—seminal vesicle—testicular cancer	0.000903	0.00817	CbGeAlD
Progesterone—NR3C2—Preimplantation Embryo—DNMT3L—testicular cancer	0.000883	0.0866	CbGpPWpGaD
Progesterone—SLC22A3—gonad—testicular cancer	0.00079	0.00714	CbGeAlD
Progesterone—SHBG—female gonad—testicular cancer	0.000778	0.00704	CbGeAlD
Progesterone—NR3C2—female gonad—testicular cancer	0.000754	0.00682	CbGeAlD
Progesterone—NR3C1—embryo—testicular cancer	0.000733	0.00664	CbGeAlD
Progesterone—CYP1B1—gonad—testicular cancer	0.000726	0.00657	CbGeAlD
Progesterone—PGR—female gonad—testicular cancer	0.000701	0.00634	CbGeAlD
Progesterone—SHBG—testis—testicular cancer	0.00069	0.00624	CbGeAlD
Progesterone—NR3C1—seminal vesicle—testicular cancer	0.000689	0.00623	CbGeAlD
Progesterone—AR—gonad—testicular cancer	0.000687	0.00622	CbGeAlD
Progesterone—ESR1—gonad—testicular cancer	0.000675	0.0061	CbGeAlD
Progesterone—CYP17A1—lymph node—testicular cancer	0.000671	0.00607	CbGeAlD
Progesterone—NR3C2—testis—testicular cancer	0.000669	0.00605	CbGeAlD
Progesterone—SLC22A3—female gonad—testicular cancer	0.000642	0.00581	CbGeAlD
Progesterone—PGR—testis—testicular cancer	0.000622	0.00563	CbGeAlD
Progesterone—SIGMAR1—female gonad—testicular cancer	0.00062	0.00561	CbGeAlD
Progesterone—CYP1B1—female gonad—testicular cancer	0.00059	0.00534	CbGeAlD
Progesterone—SLC22A3—testis—testicular cancer	0.000569	0.00515	CbGeAlD
Progesterone—AR—female gonad—testicular cancer	0.000559	0.00505	CbGeAlD
Progesterone—SIGMAR1—testis—testicular cancer	0.00055	0.00498	CbGeAlD
Progesterone—ESR1—female gonad—testicular cancer	0.000548	0.00496	CbGeAlD
Progesterone—ABCC1—female gonad—testicular cancer	0.00053	0.0048	CbGeAlD
Progesterone—CYP1B1—testis—testicular cancer	0.000523	0.00473	CbGeAlD
Progesterone—NR3C1—gonad—testicular cancer	0.000498	0.0045	CbGeAlD
Progesterone—AR—testis—testicular cancer	0.000495	0.00448	CbGeAlD
Progesterone—ESR1—testis—testicular cancer	0.000486	0.0044	CbGeAlD
Progesterone—NR3C2—lymph node—testicular cancer	0.000485	0.00439	CbGeAlD
Progesterone—ABCC1—testis—testicular cancer	0.00047	0.00426	CbGeAlD
Progesterone—PGR—lymph node—testicular cancer	0.000451	0.00408	CbGeAlD
Progesterone—NR3C1—Endoderm Differentiation—PRDM14—testicular cancer	0.000443	0.0434	CbGpPWpGaD
Progesterone—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000426	0.0418	CbGpPWpGaD
Progesterone—CYP1A1—female gonad—testicular cancer	0.000417	0.00377	CbGeAlD
Progesterone—SLC22A3—lymph node—testicular cancer	0.000413	0.00373	CbGeAlD
Progesterone—CYP3A5—female gonad—testicular cancer	0.000408	0.00369	CbGeAlD
Progesterone—NR3C1—female gonad—testicular cancer	0.000405	0.00366	CbGeAlD
Progesterone—CYP2C8—testis—testicular cancer	0.000401	0.00362	CbGeAlD
Progesterone—SIGMAR1—lymph node—testicular cancer	0.000399	0.00361	CbGeAlD
Progesterone—ABCB1—embryo—testicular cancer	0.000393	0.00355	CbGeAlD
Progesterone—CYP1B1—lymph node—testicular cancer	0.000379	0.00343	CbGeAlD
Progesterone—ABCB1—seminal vesicle—testicular cancer	0.000369	0.00334	CbGeAlD
Progesterone—AR—lymph node—testicular cancer	0.000359	0.00325	CbGeAlD
Progesterone—NR3C1—testis—testicular cancer	0.000359	0.00325	CbGeAlD
Progesterone—ESR1—lymph node—testicular cancer	0.000352	0.00319	CbGeAlD
Progesterone—ABCC1—lymph node—testicular cancer	0.000341	0.00309	CbGeAlD
Progesterone—CYP2D6—female gonad—testicular cancer	0.000301	0.00272	CbGeAlD
Progesterone—CYP1A1—lymph node—testicular cancer	0.000268	0.00242	CbGeAlD
Progesterone—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000267	0.0262	CbGpPWpGaD
Progesterone—CYP2D6—testis—testicular cancer	0.000267	0.00242	CbGeAlD
Progesterone—ABCB1—gonad—testicular cancer	0.000266	0.00241	CbGeAlD
Progesterone—NR3C1—lymph node—testicular cancer	0.00026	0.00235	CbGeAlD
Progesterone—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000249	0.0244	CbGpPWpGaD
Progesterone—ABCB1—female gonad—testicular cancer	0.000217	0.00196	CbGeAlD
Progesterone—CYP1B1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000196	0.0192	CbGpPWpGaD
Progesterone—SLC22A3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000194	0.019	CbGpPWpGaD
Progesterone—ABCB1—testis—testicular cancer	0.000192	0.00174	CbGeAlD
Progesterone—ABCC1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000189	0.0186	CbGpPWpGaD
Progesterone—CYP1B1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000183	0.018	CbGpPWpGaD
Progesterone—ESR1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000182	0.0178	CbGpPWpGaD
Progesterone—OPRK1—Peptide ligand-binding receptors—INSL3—testicular cancer	0.000178	0.0175	CbGpPWpGaD
Progesterone—CYP2A6—NRF2 pathway—SLC2A6—testicular cancer	0.000177	0.0173	CbGpPWpGaD
Progesterone—ESR1—LKB1 signaling events—STK11—testicular cancer	0.00014	0.0137	CbGpPWpGaD
Progesterone—ABCB1—lymph node—testicular cancer	0.000139	0.00126	CbGeAlD
Progesterone—SLC22A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000121	0.0119	CbGpPWpGaD
Progesterone—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000121	0.0118	CbGpPWpGaD
Progesterone—OPRK1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00012	0.0117	CbGpPWpGaD
Progesterone—CYP17A1—Biological oxidations—HPGDS—testicular cancer	0.000117	0.0115	CbGpPWpGaD
Progesterone—SLC22A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000113	0.0111	CbGpPWpGaD
Progesterone—CYP1A1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000113	0.0111	CbGpPWpGaD
Progesterone—Visual impairment—Methotrexate—testicular cancer	0.000109	0.000601	CcSEcCtD
Progesterone—Vomiting—Ifosfamide—testicular cancer	0.000108	0.000596	CcSEcCtD
Progesterone—Hypersensitivity—Cisplatin—testicular cancer	0.000108	0.000595	CcSEcCtD
Progesterone—Rash—Ifosfamide—testicular cancer	0.000107	0.000591	CcSEcCtD
Progesterone—Dermatitis—Ifosfamide—testicular cancer	0.000107	0.00059	CcSEcCtD
Progesterone—Erythema multiforme—Methotrexate—testicular cancer	0.000107	0.00059	CcSEcCtD
Progesterone—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000107	0.00059	CcSEcCtD
Progesterone—Urticaria—Etoposide—testicular cancer	0.000107	0.000588	CcSEcCtD
Progesterone—Haemoglobin—Epirubicin—testicular cancer	0.000106	0.000587	CcSEcCtD
Progesterone—Jaundice—Doxorubicin—testicular cancer	0.000106	0.000587	CcSEcCtD
Progesterone—Rhinitis—Epirubicin—testicular cancer	0.000106	0.000585	CcSEcCtD
Progesterone—Abdominal pain—Etoposide—testicular cancer	0.000106	0.000585	CcSEcCtD
Progesterone—Body temperature increased—Etoposide—testicular cancer	0.000106	0.000585	CcSEcCtD
Progesterone—Urinary tract infection—Doxorubicin—testicular cancer	0.000106	0.000585	CcSEcCtD
Progesterone—Conjunctivitis—Doxorubicin—testicular cancer	0.000106	0.000585	CcSEcCtD
Progesterone—Haemorrhage—Epirubicin—testicular cancer	0.000106	0.000584	CcSEcCtD
Progesterone—Hepatitis—Epirubicin—testicular cancer	0.000106	0.000584	CcSEcCtD
Progesterone—Eye disorder—Methotrexate—testicular cancer	0.000106	0.000583	CcSEcCtD
Progesterone—Tinnitus—Methotrexate—testicular cancer	0.000105	0.000582	CcSEcCtD
Progesterone—Asthenia—Cisplatin—testicular cancer	0.000105	0.00058	CcSEcCtD
Progesterone—Pharyngitis—Epirubicin—testicular cancer	0.000105	0.00058	CcSEcCtD
Progesterone—Cardiac disorder—Methotrexate—testicular cancer	0.000105	0.000579	CcSEcCtD
Progesterone—Urinary tract disorder—Epirubicin—testicular cancer	0.000104	0.000577	CcSEcCtD
Progesterone—Oedema peripheral—Epirubicin—testicular cancer	0.000104	0.000575	CcSEcCtD
Progesterone—Connective tissue disorder—Epirubicin—testicular cancer	0.000104	0.000574	CcSEcCtD
Progesterone—Urethral disorder—Epirubicin—testicular cancer	0.000104	0.000572	CcSEcCtD
Progesterone—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000103	0.0101	CbGpPWpGaD
Progesterone—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000103	0.000569	CcSEcCtD
Progesterone—Angiopathy—Methotrexate—testicular cancer	0.000103	0.000566	CcSEcCtD
Progesterone—Sinusitis—Doxorubicin—testicular cancer	0.000102	0.000565	CcSEcCtD
Progesterone—Immune system disorder—Methotrexate—testicular cancer	0.000102	0.000564	CcSEcCtD
Progesterone—Visual impairment—Epirubicin—testicular cancer	0.000102	0.000563	CcSEcCtD
Progesterone—Mediastinal disorder—Methotrexate—testicular cancer	0.000102	0.000562	CcSEcCtD
Progesterone—Nausea—Ifosfamide—testicular cancer	0.000101	0.000557	CcSEcCtD
Progesterone—Diarrhoea—Cisplatin—testicular cancer	0.0001	0.000553	CcSEcCtD
Progesterone—Erythema multiforme—Epirubicin—testicular cancer	0.0001	0.000552	CcSEcCtD
Progesterone—Alopecia—Methotrexate—testicular cancer	9.99e-05	0.000551	CcSEcCtD
Progesterone—Mental disorder—Methotrexate—testicular cancer	9.91e-05	0.000547	CcSEcCtD
Progesterone—Eye disorder—Epirubicin—testicular cancer	9.89e-05	0.000546	CcSEcCtD
Progesterone—Hypersensitivity—Etoposide—testicular cancer	9.88e-05	0.000545	CcSEcCtD
Progesterone—Tinnitus—Epirubicin—testicular cancer	9.87e-05	0.000544	CcSEcCtD
Progesterone—Erythema—Methotrexate—testicular cancer	9.84e-05	0.000543	CcSEcCtD
Progesterone—Malnutrition—Methotrexate—testicular cancer	9.84e-05	0.000543	CcSEcCtD
Progesterone—Haemoglobin—Doxorubicin—testicular cancer	9.84e-05	0.000543	CcSEcCtD
Progesterone—SLC22A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	9.84e-05	0.00965	CbGpPWpGaD
Progesterone—Cardiac disorder—Epirubicin—testicular cancer	9.82e-05	0.000542	CcSEcCtD
Progesterone—Rhinitis—Doxorubicin—testicular cancer	9.82e-05	0.000542	CcSEcCtD
Progesterone—Haemorrhage—Doxorubicin—testicular cancer	9.79e-05	0.00054	CcSEcCtD
Progesterone—Hepatitis—Doxorubicin—testicular cancer	9.79e-05	0.00054	CcSEcCtD
Progesterone—Pharyngitis—Doxorubicin—testicular cancer	9.72e-05	0.000536	CcSEcCtD
Progesterone—Urinary tract disorder—Doxorubicin—testicular cancer	9.67e-05	0.000534	CcSEcCtD
Progesterone—Oedema peripheral—Doxorubicin—testicular cancer	9.64e-05	0.000532	CcSEcCtD
Progesterone—Asthenia—Etoposide—testicular cancer	9.62e-05	0.000531	CcSEcCtD
Progesterone—Connective tissue disorder—Doxorubicin—testicular cancer	9.62e-05	0.000531	CcSEcCtD
Progesterone—Angiopathy—Epirubicin—testicular cancer	9.6e-05	0.00053	CcSEcCtD
Progesterone—Urethral disorder—Doxorubicin—testicular cancer	9.6e-05	0.00053	CcSEcCtD
Progesterone—Immune system disorder—Epirubicin—testicular cancer	9.56e-05	0.000527	CcSEcCtD
Progesterone—Mediastinal disorder—Epirubicin—testicular cancer	9.54e-05	0.000526	CcSEcCtD
Progesterone—Back pain—Methotrexate—testicular cancer	9.52e-05	0.000525	CcSEcCtD
Progesterone—Pruritus—Etoposide—testicular cancer	9.49e-05	0.000524	CcSEcCtD
Progesterone—Visual impairment—Doxorubicin—testicular cancer	9.43e-05	0.000521	CcSEcCtD
Progesterone—Alopecia—Epirubicin—testicular cancer	9.35e-05	0.000516	CcSEcCtD
Progesterone—Vomiting—Cisplatin—testicular cancer	9.31e-05	0.000514	CcSEcCtD
Progesterone—Vision blurred—Methotrexate—testicular cancer	9.28e-05	0.000512	CcSEcCtD
Progesterone—Mental disorder—Epirubicin—testicular cancer	9.27e-05	0.000512	CcSEcCtD
Progesterone—Erythema multiforme—Doxorubicin—testicular cancer	9.26e-05	0.000511	CcSEcCtD
Progesterone—Rash—Cisplatin—testicular cancer	9.23e-05	0.000509	CcSEcCtD
Progesterone—CYP2C19—Arachidonic acid metabolism—HPGDS—testicular cancer	9.23e-05	0.00905	CbGpPWpGaD
Progesterone—Dermatitis—Cisplatin—testicular cancer	9.22e-05	0.000509	CcSEcCtD
Progesterone—Malnutrition—Epirubicin—testicular cancer	9.21e-05	0.000508	CcSEcCtD
Progesterone—Erythema—Epirubicin—testicular cancer	9.21e-05	0.000508	CcSEcCtD
Progesterone—Diarrhoea—Etoposide—testicular cancer	9.18e-05	0.000506	CcSEcCtD
Progesterone—Eye disorder—Doxorubicin—testicular cancer	9.15e-05	0.000505	CcSEcCtD
Progesterone—Ill-defined disorder—Methotrexate—testicular cancer	9.13e-05	0.000504	CcSEcCtD
Progesterone—Tinnitus—Doxorubicin—testicular cancer	9.13e-05	0.000504	CcSEcCtD
Progesterone—OPRK1—GPCR ligand binding—INSL3—testicular cancer	9.1e-05	0.00893	CbGpPWpGaD
Progesterone—Anaemia—Methotrexate—testicular cancer	9.1e-05	0.000502	CcSEcCtD
Progesterone—Cardiac disorder—Doxorubicin—testicular cancer	9.09e-05	0.000501	CcSEcCtD
Progesterone—Flatulence—Epirubicin—testicular cancer	9.08e-05	0.000501	CcSEcCtD
Progesterone—Tension—Epirubicin—testicular cancer	9.04e-05	0.000499	CcSEcCtD
Progesterone—Nervousness—Epirubicin—testicular cancer	8.95e-05	0.000494	CcSEcCtD
Progesterone—Back pain—Epirubicin—testicular cancer	8.91e-05	0.000492	CcSEcCtD
Progesterone—Angiopathy—Doxorubicin—testicular cancer	8.88e-05	0.00049	CcSEcCtD
Progesterone—Malaise—Methotrexate—testicular cancer	8.88e-05	0.00049	CcSEcCtD
Progesterone—Dizziness—Etoposide—testicular cancer	8.87e-05	0.000489	CcSEcCtD
Progesterone—Muscle spasms—Epirubicin—testicular cancer	8.86e-05	0.000489	CcSEcCtD
Progesterone—Immune system disorder—Doxorubicin—testicular cancer	8.84e-05	0.000488	CcSEcCtD
Progesterone—Vertigo—Methotrexate—testicular cancer	8.84e-05	0.000488	CcSEcCtD
Progesterone—Mediastinal disorder—Doxorubicin—testicular cancer	8.82e-05	0.000487	CcSEcCtD
Progesterone—Nausea—Cisplatin—testicular cancer	8.7e-05	0.00048	CcSEcCtD
Progesterone—Vision blurred—Epirubicin—testicular cancer	8.68e-05	0.000479	CcSEcCtD
Progesterone—Alopecia—Doxorubicin—testicular cancer	8.65e-05	0.000477	CcSEcCtD
Progesterone—Cough—Methotrexate—testicular cancer	8.59e-05	0.000474	CcSEcCtD
Progesterone—Mental disorder—Doxorubicin—testicular cancer	8.58e-05	0.000473	CcSEcCtD
Progesterone—Ill-defined disorder—Epirubicin—testicular cancer	8.55e-05	0.000472	CcSEcCtD
Progesterone—Convulsion—Methotrexate—testicular cancer	8.53e-05	0.000471	CcSEcCtD
Progesterone—Vomiting—Etoposide—testicular cancer	8.53e-05	0.000471	CcSEcCtD
Progesterone—Malnutrition—Doxorubicin—testicular cancer	8.52e-05	0.00047	CcSEcCtD
Progesterone—Erythema—Doxorubicin—testicular cancer	8.52e-05	0.00047	CcSEcCtD
Progesterone—Anaemia—Epirubicin—testicular cancer	8.51e-05	0.00047	CcSEcCtD
Progesterone—Rash—Etoposide—testicular cancer	8.46e-05	0.000467	CcSEcCtD
Progesterone—Dermatitis—Etoposide—testicular cancer	8.45e-05	0.000466	CcSEcCtD
Progesterone—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	8.41e-05	0.00825	CbGpPWpGaD
Progesterone—Headache—Etoposide—testicular cancer	8.4e-05	0.000464	CcSEcCtD
Progesterone—Flatulence—Doxorubicin—testicular cancer	8.4e-05	0.000463	CcSEcCtD
Progesterone—Chest pain—Methotrexate—testicular cancer	8.38e-05	0.000462	CcSEcCtD
Progesterone—Myalgia—Methotrexate—testicular cancer	8.38e-05	0.000462	CcSEcCtD
Progesterone—Arthralgia—Methotrexate—testicular cancer	8.38e-05	0.000462	CcSEcCtD
Progesterone—Tension—Doxorubicin—testicular cancer	8.36e-05	0.000462	CcSEcCtD
Progesterone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	8.32e-05	0.000459	CcSEcCtD
Progesterone—Malaise—Epirubicin—testicular cancer	8.31e-05	0.000458	CcSEcCtD
Progesterone—Discomfort—Methotrexate—testicular cancer	8.28e-05	0.000457	CcSEcCtD
Progesterone—Nervousness—Doxorubicin—testicular cancer	8.28e-05	0.000457	CcSEcCtD
Progesterone—Vertigo—Epirubicin—testicular cancer	8.28e-05	0.000457	CcSEcCtD
Progesterone—Syncope—Epirubicin—testicular cancer	8.26e-05	0.000456	CcSEcCtD
Progesterone—Back pain—Doxorubicin—testicular cancer	8.24e-05	0.000455	CcSEcCtD
Progesterone—Muscle spasms—Doxorubicin—testicular cancer	8.19e-05	0.000452	CcSEcCtD
Progesterone—Palpitations—Epirubicin—testicular cancer	8.14e-05	0.000449	CcSEcCtD
Progesterone—NR3C2—Gene Expression—DNMT3L—testicular cancer	8.14e-05	0.00798	CbGpPWpGaD
Progesterone—ESR1—Plasma membrane estrogen receptor signaling—MMP2—testicular cancer	8.11e-05	0.00795	CbGpPWpGaD
Progesterone—Confusional state—Methotrexate—testicular cancer	8.1e-05	0.000447	CcSEcCtD
Progesterone—Loss of consciousness—Epirubicin—testicular cancer	8.1e-05	0.000447	CcSEcCtD
Progesterone—Cough—Epirubicin—testicular cancer	8.04e-05	0.000444	CcSEcCtD
Progesterone—Anaphylactic shock—Methotrexate—testicular cancer	8.03e-05	0.000443	CcSEcCtD
Progesterone—Vision blurred—Doxorubicin—testicular cancer	8.03e-05	0.000443	CcSEcCtD
Progesterone—PGR—Signaling by ERBB4—KITLG—testicular cancer	8.01e-05	0.00785	CbGpPWpGaD
Progesterone—Convulsion—Epirubicin—testicular cancer	7.98e-05	0.00044	CcSEcCtD
Progesterone—Infection—Methotrexate—testicular cancer	7.98e-05	0.00044	CcSEcCtD
Progesterone—Nausea—Etoposide—testicular cancer	7.97e-05	0.00044	CcSEcCtD
Progesterone—ESR1—FOXM1 transcription factor network—MMP2—testicular cancer	7.95e-05	0.0078	CbGpPWpGaD
Progesterone—Hypertension—Epirubicin—testicular cancer	7.95e-05	0.000439	CcSEcCtD
Progesterone—Ill-defined disorder—Doxorubicin—testicular cancer	7.91e-05	0.000436	CcSEcCtD
Progesterone—Nervous system disorder—Methotrexate—testicular cancer	7.88e-05	0.000435	CcSEcCtD
Progesterone—Anaemia—Doxorubicin—testicular cancer	7.88e-05	0.000435	CcSEcCtD
Progesterone—Myalgia—Epirubicin—testicular cancer	7.84e-05	0.000433	CcSEcCtD
Progesterone—Arthralgia—Epirubicin—testicular cancer	7.84e-05	0.000433	CcSEcCtD
Progesterone—Chest pain—Epirubicin—testicular cancer	7.84e-05	0.000433	CcSEcCtD
Progesterone—Anxiety—Epirubicin—testicular cancer	7.81e-05	0.000431	CcSEcCtD
Progesterone—Skin disorder—Methotrexate—testicular cancer	7.8e-05	0.000431	CcSEcCtD
Progesterone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	7.79e-05	0.00043	CcSEcCtD
Progesterone—Hyperhidrosis—Methotrexate—testicular cancer	7.77e-05	0.000429	CcSEcCtD
Progesterone—Discomfort—Epirubicin—testicular cancer	7.75e-05	0.000428	CcSEcCtD
Progesterone—Malaise—Doxorubicin—testicular cancer	7.69e-05	0.000424	CcSEcCtD
Progesterone—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	7.68e-05	0.00754	CbGpPWpGaD
Progesterone—Dry mouth—Epirubicin—testicular cancer	7.67e-05	0.000423	CcSEcCtD
Progesterone—Vertigo—Doxorubicin—testicular cancer	7.66e-05	0.000423	CcSEcCtD
Progesterone—Anorexia—Methotrexate—testicular cancer	7.66e-05	0.000423	CcSEcCtD
Progesterone—Syncope—Doxorubicin—testicular cancer	7.64e-05	0.000422	CcSEcCtD
Progesterone—Confusional state—Epirubicin—testicular cancer	7.58e-05	0.000418	CcSEcCtD
Progesterone—AR—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	7.56e-05	0.00741	CbGpPWpGaD
Progesterone—Palpitations—Doxorubicin—testicular cancer	7.53e-05	0.000416	CcSEcCtD
Progesterone—Oedema—Epirubicin—testicular cancer	7.52e-05	0.000415	CcSEcCtD
Progesterone—Anaphylactic shock—Epirubicin—testicular cancer	7.52e-05	0.000415	CcSEcCtD
Progesterone—Hypotension—Methotrexate—testicular cancer	7.51e-05	0.000414	CcSEcCtD
Progesterone—Loss of consciousness—Doxorubicin—testicular cancer	7.49e-05	0.000413	CcSEcCtD
Progesterone—Infection—Epirubicin—testicular cancer	7.47e-05	0.000412	CcSEcCtD
Progesterone—Cough—Doxorubicin—testicular cancer	7.44e-05	0.00041	CcSEcCtD
Progesterone—Shock—Epirubicin—testicular cancer	7.4e-05	0.000408	CcSEcCtD
Progesterone—Convulsion—Doxorubicin—testicular cancer	7.38e-05	0.000408	CcSEcCtD
Progesterone—Nervous system disorder—Epirubicin—testicular cancer	7.37e-05	0.000407	CcSEcCtD
Progesterone—Hypertension—Doxorubicin—testicular cancer	7.36e-05	0.000406	CcSEcCtD
Progesterone—Tachycardia—Epirubicin—testicular cancer	7.34e-05	0.000405	CcSEcCtD
Progesterone—Musculoskeletal discomfort—Methotrexate—testicular cancer	7.32e-05	0.000404	CcSEcCtD
Progesterone—Skin disorder—Epirubicin—testicular cancer	7.3e-05	0.000403	CcSEcCtD
Progesterone—Hyperhidrosis—Epirubicin—testicular cancer	7.27e-05	0.000401	CcSEcCtD
Progesterone—Insomnia—Methotrexate—testicular cancer	7.27e-05	0.000401	CcSEcCtD
Progesterone—Chest pain—Doxorubicin—testicular cancer	7.26e-05	0.0004	CcSEcCtD
Progesterone—Myalgia—Doxorubicin—testicular cancer	7.26e-05	0.0004	CcSEcCtD
Progesterone—Arthralgia—Doxorubicin—testicular cancer	7.26e-05	0.0004	CcSEcCtD
Progesterone—Anxiety—Doxorubicin—testicular cancer	7.23e-05	0.000399	CcSEcCtD
Progesterone—Paraesthesia—Methotrexate—testicular cancer	7.21e-05	0.000398	CcSEcCtD
Progesterone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	7.21e-05	0.000398	CcSEcCtD
Progesterone—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	7.19e-05	0.00705	CbGpPWpGaD
Progesterone—Discomfort—Doxorubicin—testicular cancer	7.17e-05	0.000396	CcSEcCtD
Progesterone—Anorexia—Epirubicin—testicular cancer	7.17e-05	0.000395	CcSEcCtD
Progesterone—Dyspnoea—Methotrexate—testicular cancer	7.16e-05	0.000395	CcSEcCtD
Progesterone—Somnolence—Methotrexate—testicular cancer	7.14e-05	0.000394	CcSEcCtD
Progesterone—Dry mouth—Doxorubicin—testicular cancer	7.1e-05	0.000392	CcSEcCtD
Progesterone—ABCC1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	7.09e-05	0.00695	CbGpPWpGaD
Progesterone—Dyspepsia—Methotrexate—testicular cancer	7.07e-05	0.00039	CcSEcCtD
Progesterone—Hypotension—Epirubicin—testicular cancer	7.02e-05	0.000388	CcSEcCtD
Progesterone—Confusional state—Doxorubicin—testicular cancer	7.01e-05	0.000387	CcSEcCtD
Progesterone—Decreased appetite—Methotrexate—testicular cancer	6.98e-05	0.000385	CcSEcCtD
Progesterone—Oedema—Doxorubicin—testicular cancer	6.96e-05	0.000384	CcSEcCtD
Progesterone—Anaphylactic shock—Doxorubicin—testicular cancer	6.96e-05	0.000384	CcSEcCtD
Progesterone—Gastrointestinal disorder—Methotrexate—testicular cancer	6.94e-05	0.000383	CcSEcCtD
Progesterone—Fatigue—Methotrexate—testicular cancer	6.93e-05	0.000382	CcSEcCtD
Progesterone—Infection—Doxorubicin—testicular cancer	6.91e-05	0.000381	CcSEcCtD
Progesterone—Pain—Methotrexate—testicular cancer	6.87e-05	0.000379	CcSEcCtD
Progesterone—Musculoskeletal discomfort—Epirubicin—testicular cancer	6.85e-05	0.000378	CcSEcCtD
Progesterone—Shock—Doxorubicin—testicular cancer	6.84e-05	0.000378	CcSEcCtD
Progesterone—Nervous system disorder—Doxorubicin—testicular cancer	6.82e-05	0.000376	CcSEcCtD
Progesterone—CYP1B1—Biological oxidations—HPGDS—testicular cancer	6.81e-05	0.00668	CbGpPWpGaD
Progesterone—Insomnia—Epirubicin—testicular cancer	6.8e-05	0.000375	CcSEcCtD
Progesterone—Tachycardia—Doxorubicin—testicular cancer	6.79e-05	0.000375	CcSEcCtD
Progesterone—Skin disorder—Doxorubicin—testicular cancer	6.76e-05	0.000373	CcSEcCtD
Progesterone—Paraesthesia—Epirubicin—testicular cancer	6.75e-05	0.000373	CcSEcCtD
Progesterone—Hyperhidrosis—Doxorubicin—testicular cancer	6.72e-05	0.000371	CcSEcCtD
Progesterone—Dyspnoea—Epirubicin—testicular cancer	6.7e-05	0.00037	CcSEcCtD
Progesterone—Somnolence—Epirubicin—testicular cancer	6.68e-05	0.000369	CcSEcCtD
Progesterone—Anorexia—Doxorubicin—testicular cancer	6.63e-05	0.000366	CcSEcCtD
Progesterone—AR—Integrated Breast Cancer Pathway—STK11—testicular cancer	6.63e-05	0.0065	CbGpPWpGaD
Progesterone—Feeling abnormal—Methotrexate—testicular cancer	6.62e-05	0.000365	CcSEcCtD
Progesterone—Dyspepsia—Epirubicin—testicular cancer	6.62e-05	0.000365	CcSEcCtD
Progesterone—Gastrointestinal pain—Methotrexate—testicular cancer	6.57e-05	0.000363	CcSEcCtD
Progesterone—Decreased appetite—Epirubicin—testicular cancer	6.53e-05	0.000361	CcSEcCtD
Progesterone—Hypotension—Doxorubicin—testicular cancer	6.5e-05	0.000359	CcSEcCtD
Progesterone—Gastrointestinal disorder—Epirubicin—testicular cancer	6.49e-05	0.000358	CcSEcCtD
Progesterone—Fatigue—Epirubicin—testicular cancer	6.48e-05	0.000358	CcSEcCtD
Progesterone—Constipation—Epirubicin—testicular cancer	6.43e-05	0.000355	CcSEcCtD
Progesterone—Pain—Epirubicin—testicular cancer	6.43e-05	0.000355	CcSEcCtD
Progesterone—Urticaria—Methotrexate—testicular cancer	6.38e-05	0.000352	CcSEcCtD
Progesterone—Abdominal pain—Methotrexate—testicular cancer	6.35e-05	0.00035	CcSEcCtD
Progesterone—Body temperature increased—Methotrexate—testicular cancer	6.35e-05	0.00035	CcSEcCtD
Progesterone—Musculoskeletal discomfort—Doxorubicin—testicular cancer	6.34e-05	0.00035	CcSEcCtD
Progesterone—Insomnia—Doxorubicin—testicular cancer	6.29e-05	0.000347	CcSEcCtD
Progesterone—Paraesthesia—Doxorubicin—testicular cancer	6.25e-05	0.000345	CcSEcCtD
Progesterone—Dyspnoea—Doxorubicin—testicular cancer	6.2e-05	0.000342	CcSEcCtD
Progesterone—Feeling abnormal—Epirubicin—testicular cancer	6.19e-05	0.000342	CcSEcCtD
Progesterone—Somnolence—Doxorubicin—testicular cancer	6.18e-05	0.000341	CcSEcCtD
Progesterone—SLC22A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	6.17e-05	0.00605	CbGpPWpGaD
Progesterone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	6.17e-05	0.00605	CbGpPWpGaD
Progesterone—Gastrointestinal pain—Epirubicin—testicular cancer	6.15e-05	0.000339	CcSEcCtD
Progesterone—CYP3A7—Biological oxidations—HPGDS—testicular cancer	6.14e-05	0.00602	CbGpPWpGaD
Progesterone—Dyspepsia—Doxorubicin—testicular cancer	6.12e-05	0.000338	CcSEcCtD
Progesterone—SLC10A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.11e-05	0.00599	CbGpPWpGaD
Progesterone—ESR1—ATF-2 transcription factor network—MMP2—testicular cancer	6.06e-05	0.00594	CbGpPWpGaD
Progesterone—Decreased appetite—Doxorubicin—testicular cancer	6.05e-05	0.000334	CcSEcCtD
Progesterone—Gastrointestinal disorder—Doxorubicin—testicular cancer	6.01e-05	0.000331	CcSEcCtD
Progesterone—Fatigue—Doxorubicin—testicular cancer	6e-05	0.000331	CcSEcCtD
Progesterone—Urticaria—Epirubicin—testicular cancer	5.97e-05	0.00033	CcSEcCtD
Progesterone—PGR—Signaling by ERBB4—FGFR3—testicular cancer	5.95e-05	0.00584	CbGpPWpGaD
Progesterone—Constipation—Doxorubicin—testicular cancer	5.95e-05	0.000328	CcSEcCtD
Progesterone—Pain—Doxorubicin—testicular cancer	5.95e-05	0.000328	CcSEcCtD
Progesterone—Abdominal pain—Epirubicin—testicular cancer	5.94e-05	0.000328	CcSEcCtD
Progesterone—Body temperature increased—Epirubicin—testicular cancer	5.94e-05	0.000328	CcSEcCtD
Progesterone—Hypersensitivity—Methotrexate—testicular cancer	5.92e-05	0.000327	CcSEcCtD
Progesterone—ESR1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	5.82e-05	0.00571	CbGpPWpGaD
Progesterone—Asthenia—Methotrexate—testicular cancer	5.76e-05	0.000318	CcSEcCtD
Progesterone—SLC22A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	5.75e-05	0.00564	CbGpPWpGaD
Progesterone—Feeling abnormal—Doxorubicin—testicular cancer	5.73e-05	0.000316	CcSEcCtD
Progesterone—Gastrointestinal pain—Doxorubicin—testicular cancer	5.69e-05	0.000314	CcSEcCtD
Progesterone—Pruritus—Methotrexate—testicular cancer	5.68e-05	0.000314	CcSEcCtD
Progesterone—CYP2A6—Biological oxidations—HPGDS—testicular cancer	5.63e-05	0.00552	CbGpPWpGaD
Progesterone—Hypersensitivity—Epirubicin—testicular cancer	5.54e-05	0.000306	CcSEcCtD
Progesterone—Urticaria—Doxorubicin—testicular cancer	5.53e-05	0.000305	CcSEcCtD
Progesterone—Abdominal pain—Doxorubicin—testicular cancer	5.5e-05	0.000303	CcSEcCtD
Progesterone—Body temperature increased—Doxorubicin—testicular cancer	5.5e-05	0.000303	CcSEcCtD
Progesterone—Diarrhoea—Methotrexate—testicular cancer	5.5e-05	0.000303	CcSEcCtD
Progesterone—AR—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	5.49e-05	0.00539	CbGpPWpGaD
Progesterone—PGR—Signaling by ERBB4—KIT—testicular cancer	5.47e-05	0.00536	CbGpPWpGaD
Progesterone—Asthenia—Epirubicin—testicular cancer	5.39e-05	0.000298	CcSEcCtD
Progesterone—Pruritus—Epirubicin—testicular cancer	5.32e-05	0.000294	CcSEcCtD
Progesterone—Dizziness—Methotrexate—testicular cancer	5.31e-05	0.000293	CcSEcCtD
Progesterone—OPRK1—GPCR downstream signaling—INSL3—testicular cancer	5.14e-05	0.00504	CbGpPWpGaD
Progesterone—Diarrhoea—Epirubicin—testicular cancer	5.14e-05	0.000284	CcSEcCtD
Progesterone—Hypersensitivity—Doxorubicin—testicular cancer	5.12e-05	0.000283	CcSEcCtD
Progesterone—Vomiting—Methotrexate—testicular cancer	5.11e-05	0.000282	CcSEcCtD
Progesterone—ESR1—Integrated Breast Cancer Pathway—STK11—testicular cancer	5.11e-05	0.00501	CbGpPWpGaD
Progesterone—Rash—Methotrexate—testicular cancer	5.06e-05	0.00028	CcSEcCtD
Progesterone—Dermatitis—Methotrexate—testicular cancer	5.06e-05	0.000279	CcSEcCtD
Progesterone—Headache—Methotrexate—testicular cancer	5.03e-05	0.000278	CcSEcCtD
Progesterone—Asthenia—Doxorubicin—testicular cancer	4.99e-05	0.000275	CcSEcCtD
Progesterone—Dizziness—Epirubicin—testicular cancer	4.97e-05	0.000274	CcSEcCtD
Progesterone—PGR—Gene Expression—DNMT3L—testicular cancer	4.96e-05	0.00486	CbGpPWpGaD
Progesterone—Pruritus—Doxorubicin—testicular cancer	4.92e-05	0.000272	CcSEcCtD
Progesterone—Vomiting—Epirubicin—testicular cancer	4.78e-05	0.000264	CcSEcCtD
Progesterone—Nausea—Methotrexate—testicular cancer	4.77e-05	0.000263	CcSEcCtD
Progesterone—Diarrhoea—Doxorubicin—testicular cancer	4.76e-05	0.000263	CcSEcCtD
Progesterone—Rash—Epirubicin—testicular cancer	4.74e-05	0.000262	CcSEcCtD
Progesterone—Dermatitis—Epirubicin—testicular cancer	4.74e-05	0.000261	CcSEcCtD
Progesterone—Headache—Epirubicin—testicular cancer	4.71e-05	0.00026	CcSEcCtD
Progesterone—ESR1—Signaling by ERBB4—KITLG—testicular cancer	4.7e-05	0.00461	CbGpPWpGaD
Progesterone—OPRK1—Signaling by GPCR—INSL3—testicular cancer	4.67e-05	0.00458	CbGpPWpGaD
Progesterone—Dizziness—Doxorubicin—testicular cancer	4.6e-05	0.000254	CcSEcCtD
Progesterone—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	4.57e-05	0.00448	CbGpPWpGaD
Progesterone—CYP17A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.48e-05	0.0044	CbGpPWpGaD
Progesterone—Nausea—Epirubicin—testicular cancer	4.47e-05	0.000246	CcSEcCtD
Progesterone—CYP3A5—Biological oxidations—HPGDS—testicular cancer	4.44e-05	0.00436	CbGpPWpGaD
Progesterone—Vomiting—Doxorubicin—testicular cancer	4.42e-05	0.000244	CcSEcCtD
Progesterone—Rash—Doxorubicin—testicular cancer	4.39e-05	0.000242	CcSEcCtD
Progesterone—Dermatitis—Doxorubicin—testicular cancer	4.38e-05	0.000242	CcSEcCtD
Progesterone—Headache—Doxorubicin—testicular cancer	4.36e-05	0.00024	CcSEcCtD
Progesterone—ESR1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	4.23e-05	0.00415	CbGpPWpGaD
Progesterone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	4.2e-05	0.00412	CbGpPWpGaD
Progesterone—CYP1A1—Biological oxidations—HPGDS—testicular cancer	4.2e-05	0.00411	CbGpPWpGaD
Progesterone—Nausea—Doxorubicin—testicular cancer	4.13e-05	0.000228	CcSEcCtD
Progesterone—CYP2C8—Biological oxidations—HPGDS—testicular cancer	3.85e-05	0.00377	CbGpPWpGaD
Progesterone—AR—Gene Expression—DNMT3L—testicular cancer	3.78e-05	0.0037	CbGpPWpGaD
Progesterone—ABCB11—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.6e-05	0.00353	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—INSL3—testicular cancer	3.52e-05	0.00345	CbGpPWpGaD
Progesterone—ESR1—Signaling by ERBB4—FGFR3—testicular cancer	3.49e-05	0.00343	CbGpPWpGaD
Progesterone—CYP2C19—Biological oxidations—HPGDS—testicular cancer	3.43e-05	0.00337	CbGpPWpGaD
Progesterone—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.37e-05	0.00331	CbGpPWpGaD
Progesterone—ESR1—Signaling by ERBB4—KIT—testicular cancer	3.21e-05	0.00315	CbGpPWpGaD
Progesterone—CYP2D6—Biological oxidations—HPGDS—testicular cancer	3.16e-05	0.0031	CbGpPWpGaD
Progesterone—CYP2C9—Biological oxidations—HPGDS—testicular cancer	3.13e-05	0.00307	CbGpPWpGaD
Progesterone—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	3.08e-05	0.00302	CbGpPWpGaD
Progesterone—ESR1—Gene Expression—DNMT3L—testicular cancer	2.91e-05	0.00285	CbGpPWpGaD
Progesterone—NR3C1—Gene Expression—DNMT3L—testicular cancer	2.86e-05	0.00281	CbGpPWpGaD
Progesterone—NR3C2—Gene Expression—H2AFZ—testicular cancer	2.85e-05	0.00279	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—INSL3—testicular cancer	2.76e-05	0.00271	CbGpPWpGaD
Progesterone—SLC10A1—Metabolism—HPGDS—testicular cancer	2.72e-05	0.00267	CbGpPWpGaD
Progesterone—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.7e-05	0.00265	CbGpPWpGaD
Progesterone—CYP1A2—Biological oxidations—HPGDS—testicular cancer	2.68e-05	0.00262	CbGpPWpGaD
Progesterone—CYP1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.62e-05	0.00257	CbGpPWpGaD
Progesterone—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.24e-05	0.0022	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—INSL3—testicular cancer	2.07e-05	0.00203	CbGpPWpGaD
Progesterone—CYP3A4—Biological oxidations—HPGDS—testicular cancer	2.06e-05	0.00202	CbGpPWpGaD
Progesterone—CYP17A1—Metabolism—HPGDS—testicular cancer	2e-05	0.00196	CbGpPWpGaD
Progesterone—SLC10A1—Metabolism—STK11—testicular cancer	1.98e-05	0.00194	CbGpPWpGaD
Progesterone—PGR—Gene Expression—H2AFZ—testicular cancer	1.73e-05	0.0017	CbGpPWpGaD
Progesterone—SLC22A3—Metabolism—HPGDS—testicular cancer	1.67e-05	0.00164	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.61e-05	0.00158	CbGpPWpGaD
Progesterone—ABCB11—Metabolism—HPGDS—testicular cancer	1.6e-05	0.00157	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.48e-05	0.00145	CbGpPWpGaD
Progesterone—CYP17A1—Metabolism—STK11—testicular cancer	1.45e-05	0.00142	CbGpPWpGaD
Progesterone—AR—Gene Expression—H2AFZ—testicular cancer	1.32e-05	0.0013	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.32e-05	0.00129	CbGpPWpGaD
Progesterone—SLC22A3—Metabolism—STK11—testicular cancer	1.22e-05	0.00119	CbGpPWpGaD
Progesterone—ABCC1—Metabolism—HPGDS—testicular cancer	1.2e-05	0.00118	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.2e-05	0.00118	CbGpPWpGaD
Progesterone—ABCB11—Metabolism—STK11—testicular cancer	1.17e-05	0.00114	CbGpPWpGaD
Progesterone—CYP1B1—Metabolism—HPGDS—testicular cancer	1.17e-05	0.00114	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—H2AFZ—testicular cancer	1.13e-05	0.00111	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—STK11—testicular cancer	1.12e-05	0.0011	CbGpPWpGaD
Progesterone—ABCC1—Disease—H2AFZ—testicular cancer	1.05e-05	0.00103	CbGpPWpGaD
Progesterone—CYP3A7—Metabolism—HPGDS—testicular cancer	1.05e-05	0.00103	CbGpPWpGaD
Progesterone—SLC22A2—Metabolism—HPGDS—testicular cancer	1.05e-05	0.00103	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—KITLG—testicular cancer	1.04e-05	0.00102	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.03e-05	0.00101	CbGpPWpGaD
Progesterone—ESR1—Gene Expression—H2AFZ—testicular cancer	1.02e-05	0.000998	CbGpPWpGaD
Progesterone—NR3C1—Gene Expression—H2AFZ—testicular cancer	1e-05	0.000983	CbGpPWpGaD
Progesterone—SLC22A1—Metabolism—HPGDS—testicular cancer	9.78e-06	0.000959	CbGpPWpGaD
Progesterone—ABCC1—Disease—KITLG—testicular cancer	9.67e-06	0.000948	CbGpPWpGaD
Progesterone—CYP2A6—Metabolism—HPGDS—testicular cancer	9.63e-06	0.000944	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—H2AFZ—testicular cancer	8.83e-06	0.000866	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—STK11—testicular cancer	8.78e-06	0.000861	CbGpPWpGaD
Progesterone—ABCC1—Metabolism—STK11—testicular cancer	8.75e-06	0.000858	CbGpPWpGaD
Progesterone—CYP1B1—Metabolism—STK11—testicular cancer	8.47e-06	0.00083	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—KITLG—testicular cancer	8.13e-06	0.000797	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—FGFR3—testicular cancer	7.71e-06	0.000756	CbGpPWpGaD
Progesterone—CYP3A7—Metabolism—STK11—testicular cancer	7.63e-06	0.000749	CbGpPWpGaD
Progesterone—SLC22A2—Metabolism—STK11—testicular cancer	7.62e-06	0.000747	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—HPGDS—testicular cancer	7.59e-06	0.000745	CbGpPWpGaD
Progesterone—ABCC1—Disease—FGFR3—testicular cancer	7.19e-06	0.000705	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—HPGDS—testicular cancer	7.18e-06	0.000704	CbGpPWpGaD
Progesterone—SLC22A1—Metabolism—STK11—testicular cancer	7.1e-06	0.000697	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—KIT—testicular cancer	7.08e-06	0.000694	CbGpPWpGaD
Progesterone—CYP2A6—Metabolism—STK11—testicular cancer	7e-06	0.000686	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—H2AFZ—testicular cancer	6.62e-06	0.000649	CbGpPWpGaD
Progesterone—ABCC1—Disease—KIT—testicular cancer	6.6e-06	0.000647	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—STK11—testicular cancer	6.58e-06	0.000645	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—HPGDS—testicular cancer	6.58e-06	0.000645	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—KITLG—testicular cancer	6.09e-06	0.000597	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—FGFR3—testicular cancer	6.04e-06	0.000592	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—HPGDS—testicular cancer	5.87e-06	0.000576	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—HPGDS—testicular cancer	5.73e-06	0.000562	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—KIT—testicular cancer	5.54e-06	0.000544	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—STK11—testicular cancer	5.52e-06	0.000541	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—HPGDS—testicular cancer	5.4e-06	0.00053	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—HPGDS—testicular cancer	5.35e-06	0.000525	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—STK11—testicular cancer	5.21e-06	0.000511	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—STK11—testicular cancer	4.78e-06	0.000469	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—HPGDS—testicular cancer	4.58e-06	0.000449	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—FGFR3—testicular cancer	4.53e-06	0.000444	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—STK11—testicular cancer	4.27e-06	0.000418	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—STK11—testicular cancer	4.16e-06	0.000408	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—KIT—testicular cancer	4.15e-06	0.000407	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—STK11—testicular cancer	3.92e-06	0.000385	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—STK11—testicular cancer	3.89e-06	0.000381	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—HPGDS—testicular cancer	3.53e-06	0.000346	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—STK11—testicular cancer	3.32e-06	0.000326	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—STK11—testicular cancer	2.57e-06	0.000252	CbGpPWpGaD
